GE HealthCare Technologies Inc. (NASDAQ:GEHC) Shares Bought by New York Life Investment Management LLC

New York Life Investment Management LLC raised its position in GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 8.3% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 61,406 shares of the company’s stock after buying an additional 4,702 shares during the quarter. New York Life Investment Management LLC’s holdings in GE HealthCare Technologies were worth $4,801,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. LGT Financial Advisors LLC increased its stake in GE HealthCare Technologies by 1,673.3% in the 3rd quarter. LGT Financial Advisors LLC now owns 266 shares of the company’s stock valued at $25,000 after buying an additional 251 shares during the period. Capital Performance Advisors LLP purchased a new stake in shares of GE HealthCare Technologies during the 3rd quarter worth $26,000. Ashton Thomas Securities LLC purchased a new stake in shares of GE HealthCare Technologies during the 3rd quarter worth $26,000. Darwin Wealth Management LLC purchased a new stake in shares of GE HealthCare Technologies during the 3rd quarter worth $31,000. Finally, Continuum Advisory LLC boosted its position in shares of GE HealthCare Technologies by 101.8% during the 3rd quarter. Continuum Advisory LLC now owns 333 shares of the company’s stock worth $31,000 after purchasing an additional 168 shares in the last quarter. 82.06% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have commented on GEHC shares. Citigroup boosted their target price on shares of GE HealthCare Technologies from $103.00 to $110.00 and gave the stock a “buy” rating in a research report on Thursday, February 13th. Wells Fargo & Company boosted their target price on shares of GE HealthCare Technologies from $96.00 to $103.00 and gave the stock an “overweight” rating in a research report on Friday, February 14th. Finally, Jefferies Financial Group upgraded shares of GE HealthCare Technologies from a “hold” rating to a “buy” rating and boosted their target price for the stock from $95.00 to $103.00 in a research report on Wednesday, January 8th. One analyst has rated the stock with a sell rating, three have issued a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $97.67.

GE HealthCare Technologies Price Performance

GE HealthCare Technologies stock opened at $87.35 on Friday. GE HealthCare Technologies Inc. has a 52 week low of $74.51 and a 52 week high of $94.80. The company has a quick ratio of 0.83, a current ratio of 1.04 and a debt-to-equity ratio of 0.88. The firm’s 50-day simple moving average is $86.17 and its 200 day simple moving average is $86.10. The firm has a market capitalization of $39.94 billion, a PE ratio of 20.17, a P/E/G ratio of 3.19 and a beta of 1.15.

GE HealthCare Technologies (NASDAQ:GEHC) last released its earnings results on Thursday, February 13th. The company reported $1.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.26 by $0.19. The company had revenue of $5.32 billion for the quarter, compared to analyst estimates of $5.33 billion. GE HealthCare Technologies had a net margin of 10.13% and a return on equity of 25.74%. On average, equities research analysts predict that GE HealthCare Technologies Inc. will post 4.68 EPS for the current fiscal year.

GE HealthCare Technologies Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.